健脾益气方在结直肠癌患者围手术期的临床应用评价  

Clinical evaluation of Jianpi Yiqi Formula in perioperative period of patients with colorectal cancer

作　　者：蒋海涛[1] 孙逊[1] 章学林[1] 林天碧[1] 许阳贤[1] 侯佳伟 JIANG Haitao;SUN Xun;ZHANG Xuelin;LIN Tianbi;XU Yangxian;HOU Jiawei(Department of Gastrointestinal Surgery,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)

机构地区：[1]上海中医药大学附属龙华医院胃肠外科,上海200032

出　　处：《上海中医药大学学报》2020年第2期22-25,共4页Academic Journal of Shanghai University of Traditional Chinese Medicine

基　　金：上海市海派中医流派传承人才培养项目(LH01.42.002)。

摘　　要：目的:评价健脾益气方应用于结直肠癌患者围手术期,对调节细胞免疫、促进术后恢复的价值。方法:将65例拟行手术的结直肠癌患者随机分为治疗组(32例)和对照组(33例)。对照组予腹腔镜下结直肠癌根治术及常规围手术期处理,治疗组在对照组治疗措施的基础上于术前及术后加用健脾益气方。观察两组术后肛门首次排气时间、住院天数,比较免疫相关指标、中医证候积分的变化情况。结果:①治疗组脱落3例,对照组脱落4例,最终完成试验者58例,治疗组、对照组各29例。②术后第1天与治疗前组内比较,两组CD3^+、CD4^+水平及CD4^+/CD8^+值均降低(P<0.05);术后第7天与治疗前组内比较,两组CD3^+、CD8^+水平均降低(P<0.05),治疗组CD4^+/CD8^+值升高(P<0.05),而对照组CD4^+/CD8^+值降低(P<0.05);术后第7天与术后第1天组内比较,两组CD3^+、CD4^+水平及CD4^+/CD8^+值均升高(P<0.05)。术后第1天、术后第7天组间比较,治疗组CD4^+水平及CD4^+/CD8^+值高于对照组(P<0.05)。③治疗后,两组中医证候积分均较治疗前减少(P<0.05);治疗后组间比较,治疗组中医证候积分低于对照组(P<0.05)。④治疗组术后首次排气时间早于对照组、住院天数少于对照组,差异有统计学意义(P<0.05)。结论:在结直肠癌围手术期加用健脾益气方可以调节细胞免疫,有利于减轻机体的应激状态,改善临床症状,促进术后恢复。Objective:To observe the effects of Jianpi Yiqi Formula in regulating cellular immunity and promoting postoperative recovery and evaluate its value in the perioperative period of colorectal cancer patients. Methods: Sixty-five colorectal cancer patients scheduled for operation were randomly divided into the treatment group(32 cases) and control group(33 cases). The control group was treated with laparoscopic radical resection of colorectal cancer and routine perioperative treatment, and the treatment group was treated with Jianpi Yiqi Formula before and after operation based on the treatment for the control group. The time of first anal exhaust after operation and the days of hospitalization were observed in the two groups, and the changes of immune related indexes and Chinese medical syndrome score were compared. Results: ①Three cases in the treatment group and four cases in the control group fell off. Finally, 58 cases completed the trial, among 29 cases in the treatment group and 29 cases in the control group. ② Compared with that before treatment, the levels of CD3^+, CD4^+ and the value of CD4^+/CD8^+ in both groups were decreased on the first day after operation(P<0.05). Compared with that before treatment, the levels of CD3^+ and CD8^+ in both groups were decreased on the 7 th day after operation(P<0.05), the value of CD4^+/CD8^+ in the treatment group was increased(P<0.05), and the value of CD4^+/CD8^+ in the control group was decreased(P<0.05). Compared with that on the first day after operation, the levels of CD3^+, CD4^+ and the value of CD4^+/CD8^+ in both groups were increased on the 7 th day after operation(P<0.05). On the 1 st and 7 th day after operation, the level of CD4^+and the value of CD4^+/CD8^+in the treatment group were higher than those in the control group( P<0.05).(3)Compared with that before treatment,the score of Chinese medical syndrome in both groups was decreased after treatment( P<0.05). After treatment,the score of Chinese medical syndrome in the treatment group was lower tha

关 键 词：结直肠癌 围手术期 健脾益气方 细胞免疫 术后恢复 

分 类 号：R735.34[医药卫生—肿瘤]